Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS . Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.
Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239.
Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17: 928–942.
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.
Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012; 97: 1431–1438.
Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014; 123: 640–646.
International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17: 779–790.
Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307: 906–922.
Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N . Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma and exposure-response in CLL. CPT Pharmacometrics Syst Pharmacol 2014; 3: e144.
Kastbom A, Ahmadi A, Soderkvist P, Skogh T . The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology 2005; 44: 1294–1298.
Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A . A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6: 1.
We thank the patients and their treating physicians who participated in the trials. This work was presented in part at the Annual Meeting of the German, Austrian and Swiss Society of Hematology and Oncology (Leipzig, Germany, 14–18 October 2016) and the Annual Meeting of the American Society of Hematology (San Diego, USA, 2–6 December 2016). The CLL2M and CLL10 trials were conducted as investigator-initiated trials by the GCLLSG. They were supported by research grants from Roche Pharma AG, Mundipharma, and a grant from the German Federal Ministry of Education. The CLL8 study was conducted as an investigator-initiated trial by the GCLLSG from 2003 to 2004 and afterwards sponsored by F Hoffmann-La Roche.
OA: Travel grant, honoraria from Roche. SR, JB: Travel grant, honoraria from Roche. AMF: Travel grant, honoraria from Roche, Mundipharma. PC: Travel grant, honoraria and research funding from Roche, Mundipharma. JvT: Travel grant, honoraria, research funding from Roche. CM: Travel grant from Mundipharma. MB: Honoraria from Roche, Mundipharma. MD: Honoria, research funding from Roche, Mundipharma. MK: Honoraria, research funding from Roche. SS: Travel grant, honoraria from Roche. MGK: Travel grants, honoraria from Roche. UJ: Honoraria from Roche. CMW: Grants and personal fees from Hoffmann-La Roche, Mundipharma. KF: Travel grant from Roche. VG: Research funding, honoraria from Roche. MH: Honoraria from Roche, Mundipharma. BE: Honoraria, research funding from Roche, Mundipharma. GH: Honoria, personal fees from Mundipharma, Roche.
Supplementary Information accompanies this paper on the Leukemia website
About this article
Cite this article
Al-Sawaf, O., Robrecht, S., Bahlo, J. et al. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia 31, 2251–2253 (2017) doi:10.1038/leu.2017.221